Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This study found that metabolic syndrome significantly affects the response to benign prostatic hyperplasia medications, impacting clinical outcomes such as symptom scores, prostate volume, and quality of life among male patients.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

This study found that one year of finasteride treatment significantly reduced PSA levels and prostate volume in men with elevated PSA and negative prior biopsy, potentially aiding prostate cancer diagnosis.

This study found that tamsulosin and finasteride may improve cardiac function and reduce prostatic volume in elderly male patients with chronic heart failure and benign prostatic hyperplasia.

CEC levels may be a useful marker for predicting prostate cancer progression.

Large prostate patients more likely to have hair loss.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

This study found that in beagles with benign prostate hyperplasia, finasteride treatment increased blood volume and decreased vessel leakiness in the prostate's parenchymal zone as shown by dynamic contrast-enhanced MRI.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This study found that terazosin hydrochloride, when used with finasteride, improved prostate volume and lowered blood pressure in BPH patients with high blood pressure, although the overall treatment effect was not significantly different from controls.

In this study, androgenetic alopecia patients with thin hair were found to have a higher likelihood of experiencing prostatic enlargement and related urinary symptoms compared to those with thicker hair.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

This study found that severe obesity is positively associated with more severe lower urinary tract symptoms compared to moderate obesity in patients with prostatic enlargement.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

This study demonstrated that 12 months of 5 mg daily finasteride treatment reduced prostate volume, dihydrotestosterone, and prostate-specific antigen levels, while improving urinary flow rates and symptom scores in benign prostatic hyperplasia patients.